Robotic vs Laparoscopic Surgery for Middle and Low Rectal Cancer
JAMA · 08.07.2025 · 334 (2) · 136
DOI: 10.1001/jama.2025.8123 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA, erschienen am 08.07.2025. Verfasst von Qingyang Feng und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Zhongshan Hospital Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Adenocarcinoma, Laparoscopy, Rectal Neoplasms, Robotic Surgical Procedures. Die Arbeit wurde bisher 171-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Robotic surgery for rectal cancer is widely used, but data on long-term oncological outcomes are still lacking.
Objective
To compare the 3-year locoregional recurrence rates of middle and low rectal cancer in patients who underwent robotic surgery vs conventional laparoscopic surgery. Design, Setting, and Participants In this multicenter, superiority, randomized clinical trial, patients with middle or low rectal adenocarcinoma (cT1-T3, N0-N1, or ycT1-T3 Nx) and no distant metastasis were enrolled at 11 centers across 8 provinces in China from July 2016 to December 2020. Among the 1742 consecutive patients assessed for eligibility, 1240 were eligible and randomized. Follow-up continued until December 31, 2023.
Interventions
Patients were randomized 1:1 to undergo robotic or conventional laparoscopic rectal cancer resection. Main Outcomes and Measures The primary outcome was the 3-year locoregional recurrence rate. The primary analysis was performed as randomized, but excluded patients deemed ineligible after randomization. The secondary outcomes included disease-free survival; overall survival; and urinary, sexual, and defecation function.
Results
Of the 1240 patients enrolled, 1171 were included in the primary analysis (586 in the robotic surgery group; mean age, 59.1 [SD, 11.0] years; and 356 were men [60.8%] vs 585 in the laparoscopic surgery group; mean age, 60.7 [SD, 9.8] years; and 354 were men [60.5%]). The median follow-up time was 43.0 months (IQR, 36.7-60.0 months). The 3-year locoregional recurrence rate was 1.6% (95% CI, 0.6%-2.6%) in the robotic group vs 4.0% (95% CI, 2.4%-5.6%) in the laparoscopic group (hazard ratio [HR], 0.45 [95% CI, 0.22-0.92], log-rank P = .03; adjusted HR, 0.39 [95% CI, 0.19-0.80]). The 3-year disease-free survival rate was higher in the robotic group (87.2%) vs the laparoscopic group (83.4%) (HR, 0.74 [95% CI, 0.56-0.98], log-rank P = .04; adjusted HR, 0.67 [95% CI, 0.50-0.89]). No significant between-group difference was observed in 3-year overall survival (94.7% in the robotic group vs 93.0% in the laparoscopic group). Patients in the robotic group also had better urinary function, male and female sexual function, and defecation function at 3 and 6 months after surgery and better urinary function and male sexual function at 12 months after surgery. Conclusions and Relevance Compared with conventional laparoscopic surgery, robotic surgery significantly improved long-term oncological outcomes in patients with middle or low rectal cancer. With additional real-world clinical data and modern, improved training programs for surgeons, robotic surgery could be the preferred choice for patients with middle or low rectal cancer. Trial Registration ClinicalTrials.gov Identifier: NCT02817126
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Colorectal Surgery, Zhongshan Hospital Fudan University, Shanghai, China.
- Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Technology, Shanghai, China.
- Department of Colorectal Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of General Surgery, First Affiliated Hospital of Nanchang University, Nanchang, China.
- Department of General Surgery, Southwest Hospital, Army Medical University, Chongqing, China.
- Department of General Surgery, First Medical Center, PLA General Hospital, Beijing, China.
Zitieren
APA
Feng, Q., Yuan, W., Li, T., Tang, B., Jia, B., Zhou, Y., Zhang, W., Zhao, R., Zhang, C., Cheng, L., Zhang, X., Wei, Y., Liang, F., He, G., Xu, J., & REAL Study Group (2025). Robotic vs Laparoscopic Surgery for Middle and Low Rectal Cancer. JAMA, 334(2), 136. https://doi.org/10.1001/jama.2025.8123
Vancouver
Feng Q, Yuan W, Li T, Tang B, Jia B, Zhou Y, et al. Robotic vs Laparoscopic Surgery for Middle and Low Rectal Cancer. JAMA. 2025;334(2):136. doi:10.1001/jama.2025.8123
BibTeX
@article{Feng2025,
author = {Feng, Qingyang and Yuan, Weitang and Li, Taiyuan and Tang, Bo and Jia, Baoqing and Zhou, Yanbing and Zhang, Wei and Zhao, Ren and Zhang, Cheng and Cheng, Longwei and Zhang, Xiaoqiao and Wei, Ye and Liang, Fei and He, Guodong and Xu, Jianmin and REAL Study Group, REAL Study Group},
title = {Robotic vs Laparoscopic Surgery for Middle and Low Rectal Cancer},
journal = {JAMA},
year = {2025},
volume = {334},
number = {2},
pages = {136},
doi = {10.1001/jama.2025.8123}
}
EUVIMED